SB 873: Prescription drugs: cost sharing.
- Session Year: 2023-2024
- House: Senate
- Latest Version Date: 2023-02-17
Current Status:
Failed
(2023-09-01: September 1 hearing: Held in committee and under submission.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
(1)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care under authority of the Director of the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance under the authority of the Insurance Commissioner. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price.
This bill, commencing no later than January 1, 2025, would require an enrollees or insureds defined cost sharing for each prescription drug to be calculated at the point of sale based on a price that is reduced by an amount equal to 90% of all rebates received, or to be received, in connection with the dispensing or administration of the drug. The bill would require a health care service plan or health insurer to, among other things, pass through to each enrollee or insured at the point of sale a good faith estimate of the enrollees or insureds decrease in cost sharing. The bill would require a health care service plan or health insurer to calculate an enrollees or insureds defined cost sharing and provide that information to the dispensing pharmacy, as specified. The bill would require the department and the commissioner to submit an annual report on the impact of these provisions to the appropriate policy committees of the Legislature, as specified. The bill would make these provisions inoperative on January 1, 2027.
(2)Existing law requires a health care service plan or health insurer that files certain rate information to report to the appropriate department specified cost information regarding covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs, dispensed as provided.
This bill, until January 1, 2027, would require a health care service plan or health insurer to report additional information on the above-described point of sale provision.
(3)Because a willful violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)(1)Commencing no later than January 1, 2025, an enrollees defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least 90 percent of all rebates received, or to be received, in connection with the dispensing or administration of the drug.
(2)The health care service plan shall pass through to each enrollee at the point of sale a good faith estimate of the enrollees decrease in cost sharing required pursuant to this subdivision.
(3)In addition to the pass through at the point of sale described in paragraph (2), the health care service plan shall provide the enrollee with an end-of-calendar-year reconciliation for any cost-sharing reductions owed to the enrollee pursuant to this subdivision that were not passed on to the enrollee through the estimated amount at the point of sale. This paragraph does not authorize a health care service plan to recover from an enrollee any inaccurate estimate of cost-sharing reductions.
(b)Each health care service plan shall, either directly or indirectly through its agents, calculate the enrollees defined cost sharing and provide the dispensing pharmacy with the enrollees defined cost sharing for each prescription drug as required pursuant to subdivision (a).
(c)This section does not prohibit a health care service plan from decreasing an enrollees defined cost sharing by an amount greater than that required pursuant to subdivision (a).
(d)(1)This section shall not be interpreted or implemented in a manner inconsistent with federal law. The provisions of this section are severable. If a provision of this section or its application is held invalid or incapable of being enforced against a health care service plan due to a conflict with federal requirements, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
(2)Cost sharing, including copayments, coinsurance, deductibles, and any other form of cost sharing shall be consistent with Section 1342.73 and other provisions of this article.
(e)For purposes of this section:
(1)Defined cost sharing means a deductible payment or coinsurance amount imposed on an enrollee for a covered prescription drug under the enrollees health care service plan contract.
(2)Health care service plan has the meaning set forth in Section 1345 and includes a specialized health care service plan.
(3)Price protection rebate means a negotiated price concession that accrues directly or indirectly to a health care service plan, or other party on behalf of the health care service plan, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.
(4)Rebate means both of the following:
(A)Negotiated price concessions, including base price concessions, whether or not described as a rebate, and reasonable, good faith estimates of price protection rebates and performance-based price concessions from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug that may accrue directly or indirectly to the health care service plan, or other party on behalf of the health care service plan, including, but not limited to, health care service plan-owned pharmacy benefit managers, during a calendar year.
(B)Reasonable, good faith estimates of negotiated price concessions, fees, and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the health care service plan and serve to reduce the health care service plans liabilities for a prescription drug.
(f)(1)On or before March 1 each year, the department shall provide a report on this sections impact on drug prices and health care premium rates to the appropriate policy committees of the Legislature.
(2)The report required to be submitted pursuant to paragraph (1) shall be submitted in compliance with Section 9795 of the Government Code.
(g)Subdivisions (a) to (f), inclusive, shall become inoperative on January 1, 2027.
(h)This section shall remain in effect only until January 1, 2028, and as of that date is repealed.
SEC. 2.Section 1367.243 of the Health and Safety Code is amended to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)(A)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)(i)The 25 most frequently prescribed drugs.
(B)(ii)The 25 most costly drugs by total annual plan spending.
(C)(iii)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(iv)The 25 most frequently prescribed drugs with a point-of-sale rebate pursuant to Section 1367.52.
(v)The 25 most costly drugs by total annual plan spending with a point-of-sale rebate pursuant to Section 1367.52.
(B)For each plan with a prescription drug benefit that the health care service plan issued for delivery, renewed, amended, or continued during the immediately preceding calendar year, all of the following:
(i)The aggregate dollar amount of all rebates that the health care service plan or a designee of the health care service plan collected directly or indirectly from all pharmaceutical manufacturers in connection with the design and administration of the plan, which are attributable to health care service plan enrollee drug utilization during that calendar year.
(ii)The percentage of those rebates that the health care service plan made available to enrollees to reduce cost sharing for prescription drugs at the point of sale.
(iii)The percentage of those rebates that the health care service plan utilized to reduce the portion of premiums allocated to each of prescription drug expenditures, hospital expenditures, medical expenditures, administrative costs, and other expenditures.
(iv)The aggregate dollar amount of all health care service plan administrative service fees that the health care service plan or a designee of the health care service plan paid to a pharmacy benefit manager or its designee in connection with the pharmacy benefit managers managing or administering the pharmacy benefit and administering, invoicing, allocating, and collecting rebates.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs and rebates on health care premiums. premiums, cost sharing, and payments to pharmacy benefit managers. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans. plans, or the identity of a specific manufacturer, the prices charged for specific drugs or classes of drugs, or the amount of any rebates provided for specific drugs or classes of drugs, or otherwise have the potential to compromise the financial, competitive, or proprietary nature of any of that information.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2019, the department shall publish on its Internet Web site internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
(g)For purposes of this section:
(1)Health care service plan has the same meaning set forth in Section 1345, and includes a specialized health care service plan.
(2)Health care service plan administrative service fees means fees or payments from a health care service plan to, or otherwise retained by, a pharmacy benefit manager or its designee pursuant to a contract between a pharmacy benefit manager or affiliate and the health care service plan in connection with the pharmacy benefit managers managing or administering the pharmacy benefit and administering, invoicing, allocating and collecting rebates.
(3)Price protection rebate means a negotiated price concession that accrues directly or indirectly to a health care service plan, or other party on behalf of the health care service plan, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.
(4)Rebate means both of the following:
(A)Negotiated price concessions, including base price concessions, whether or not described as a rebate, and reasonable, good faith estimates of price protection rebates and performance-based price concessions from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug that may accrue directly or indirectly to the health care service plan, or other party on behalf of the health care service plan, including health care service plan-owned pharmacy benefit managers, during a calendar year.
(B)Reasonable, good faith estimates of negotiated price concessions, fees, and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the health care service plan and serve to reduce the health care service plans liabilities for a prescription drug.
(h)This section shall remain in effect only until January 1, 2027, and as of that date is repealed.
SEC. 3.Section 1367.243 is added to the Health and Safety Code, to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(b)(1)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to an individual health care service plan.
(2)By January 1 of each year, the department shall publish on its internet website the report required pursuant to paragraph (1).
(3)After the report required pursuant to paragraph (2) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(c)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
(d)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(e)This section shall become operative on January 1, 2027.
SEC. 4.Section 10123.66 is added to the Insurance Code, to read:10123.66.(a)(1)Commencing no later than January 1, 2025, an insureds defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least 90 percent of all rebates received, or to be received, in connection with the dispensing or administration of the drug.
(2)The health insurer shall pass through to each insured at the point of sale a good faith estimate of the insureds decrease in cost sharing required pursuant to this subdivision.
(3)In addition to the pass through at the point of sale described in paragraph (2), the health insurer shall provide the insured with an end-of-calendar-year reconciliation for any cost-sharing reductions owed to the insured pursuant to this subdivision that were not passed on to the insured through the estimated amount at the point of sale. This paragraph does not authorize a health insurer to recover from an insured any inaccurate estimate of cost-sharing reductions.
(b)Each health insurer shall, either directly or indirectly through its agents, calculate the insureds defined cost sharing and provide the dispensing pharmacy with the insureds defined cost sharing for each prescription drug as required pursuant to subdivision (a).
(c)This section does not prohibit a health insurer from decreasing an insureds defined cost sharing by an amount greater than that required pursuant to subdivision (a).
(d)(1)This section shall not be interpreted or implemented in a manner inconsistent with federal law. The provisions of this section are severable. If a provision of this section or its application is held invalid or incapable of being enforced against a health insurer due to a conflict with federal requirements, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
(2)Cost sharing, including copayments, coinsurance, deductibles, and any other form of cost sharing shall be consistent with Section 10123.1932 and other provisions of this chapter.
(e)For purposes of this section:
(1)Defined cost sharing means a deductible payment or coinsurance amount imposed on an insured for a covered prescription drug under the insureds health insurance policy.
(2)Health insurer includes any health insurer holding a certificate of authority pursuant to Article 3 (commencing with Section 699) of Chapter 1 of Part 2 of Division 1.
(3)Price protection rebate means a negotiated price concession that accrues directly or indirectly to a health insurer, or other party on behalf of the health insurer, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.
(4)Rebate means both of the following:
(A)Negotiated price concessions, including base price concessions, whether or not described as a rebate, and reasonable, good faith estimates of price protection rebates and performance-based price concessions from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug that may accrue directly or indirectly to the health insurer, or other party on behalf of the health insurer, including, but not limited to, health insurer-owned pharmacy benefit managers, during a calendar year.
(B)Reasonable, good faith estimates of negotiated price concessions, fees, and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the health insurer and serve to reduce the health insurers liabilities for a prescription drug.
(f)(1) On or before March 1 of each year, the commissioner shall provide a report on this sections impact on drug prices and health care premium rates to the appropriate policy committees of the Legislature.
(2)The report required to be submitted pursuant to paragraph (1) shall be submitted in compliance with Section 9795 of the Government Code.
(g)Subdivisions (a) to (f), inclusive, of this section shall become inoperative on January 1, 2027.
(h)This section shall remain in effect only until January 1, 2028, and as of that date is repealed.
SEC. 5.Section 10123.205 of the Insurance Code is amended to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)(A)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)(i)The 25 most frequently prescribed drugs.
(B)(ii)The 25 most costly drugs by total annual plan spending.
(C)(iii)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(iv)The 25 most frequently prescribed drugs with a point-of-sale rebate pursuant to Section 10123.66.
(v)The 25 most costly drugs by total annual health insurer spending with a point-of-sale rebate pursuant to Section 10123.66.
(B)For each plan with a prescription drug benefit that the health insurer issued for delivery, renewed, amended, or continued during the immediately preceding calendar year:
(i)The aggregate dollar amount of all rebates that the health insurer or a designee of the health insurer collected directly or indirectly from all pharmaceutical manufacturers in connection with the design and administration of the plan, which are attributable to insured drug utilization during that calendar year.
(ii)The percentage of those rebates that the health insurer made available to insureds to reduce cost sharing for prescription drugs at the point of sale.
(iii)The percentage of those rebates that the health insurer utilized to reduce the portion of premiums allocated to each of prescription drug expenditures, hospital expenditures, medical expenditures, administrative costs, and other expenditures.
(iv)The aggregate dollar amount of all health insurer administrative service fees that the health insurer or a designee of the health insurer paid to a pharmacy benefit manager or its designee in connection with the pharmacy benefit managers managing or administering the pharmacy benefit and administering, invoicing, allocating, and collecting rebates.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs and rebates on health care premiums. premiums, cost sharing, and payments to pharmacy benefit managers. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers. insurers, or the identity of a specific manufacturer, the prices charged for specific drugs or classes of drugs, or the amount of any rebates provided for specific drugs or classes of drugs, or otherwise have the potential to compromise the financial, competitive, or proprietary nature of any of that information.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2018, the department shall publish on its Internet Web site internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
(g)For purposes of this section:
(1)Health insurer includes any entity licensed by the department or holding a valid certificate of authority pursuant to Article 3 (commencing with Section 699) of Chapter 1 of Part 2 of Division 1.
(2)Health insurer administrative service fees means fees or payments from a health insurer to, or otherwise retained by, a pharmacy benefit manager or its designee pursuant to a contract between a pharmacy benefit manager or affiliate and the health insurer in connection with the pharmacy benefit managers managing or administering the pharmacy benefit and administering, invoicing, allocating and collecting rebates.
(3)Price protection rebate means a negotiated price concession that accrues directly or indirectly to a health insurer, or other party on behalf of the health insurer, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.
(4)Rebate means both of the following:
(A)Negotiated price concessions, including base price concessions, whether or not described as a rebate, and reasonable, good faith estimates of price protection rebates and performance-based price concessions from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug that may accrue directly or indirectly to the health insurer, or other party on behalf of the health insurer, including, but not limited to, health insurer-owned pharmacy benefit managers, during a calendar year.
(B)Reasonable, good faith estimates of negotiated price concessions, fees, and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the health insurer and serve to reduce the health insurers liabilities for a prescription drug.
(h)This section shall remain in effect only until January 1, 2027, and as of that date is repealed.
SEC. 6.Section 10123.205 is added to the Insurance Code, to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(b)(1)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to an individual health insurer.
(2)By January 1 of each year, the department shall publish on its internet website the report required pursuant to paragraph (1).
(3)After the report required pursuant to paragraph (2) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(c)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
(d)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(e)This section shall become operative on January 1, 2027.
SEC. 7.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Sep 1, 2023 | September 1 hearing: Held in committee and under submission. |
| Aug 23, 2023 | August 23 set for first hearing. Placed on suspense file. |
| Jul 12, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 13. Noes 1.) (July 11). Re-referred to Com. on APPR. |
| Jun 15, 2023 | Referred to Com. on HEALTH. |
| Jun 1, 2023 | In Assembly. Read first time. Held at Desk. |
| May 31, 2023 | Read third time. Passed. (Ayes 28. Noes 2. Page 1386.) Ordered to the Assembly. |
| May 18, 2023 | From committee: Do pass. (Ayes 5. Noes 2. Page 1186.) (May 18). |
| May 18, 2023 | Read second time. Ordered to third reading. |
| May 12, 2023 | Set for hearing May 18. |
| May 1, 2023 | May 1 hearing: Placed on APPR suspense file. |
| Apr 21, 2023 | Set for hearing May 1. |
| Apr 20, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 1. Page 832.) (April 19). Re-referred to Com. on APPR. |
| Apr 3, 2023 | Set for hearing April 19. |
| Mar 1, 2023 | Referred to Com. on HEALTH. |
| Feb 21, 2023 | From printer. May be acted upon on or after March 20. |
| Feb 17, 2023 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jul 11, 2023 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| May 31, 2023 | Senate 3rd Reading SB873 Bradford | Senate Floor |
Passed |
|
| May 18, 2023 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| May 1, 2023 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 19, 2023 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Albie Aware Breast Cancer Foundation | ** Support | |
| Alliance for Patient Access | ** Support | |
| Alliance for Transparent and Affordable Prescriptions | ** Support | |
| Als Association The | ** Support | |
| American Diabetes Association | ** Support | |
| American Legion, Department Of California | ** Support | |
| AmericaS Health Insurance Plans | ** Against | |
| Amvets, Department Of California | ** Support | |
| Applied Pharmacy Solutions | ** Support | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| Bay Area Cancer Connections | ** Support | |
| Biocom California | ** Support | |
| California Academy Of Family Physicians | ** Support | |
| California Access Coalition | ** Support | |
| California Association Of County Veterans Service Officers | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Black Health Network | ** Support | |
| California Chamber Of Commerce | ** Against | |
| California Chronic Care Coalition | ** Support | |
| California Council Of Community Behavioral Health Agencies | ** Support | |
| California Health Collaborative | ** Support | |
| California Hepatitis C Task Force | ** Support | |
| California League of United Latin American Citizens | ** Support | |
| California Life Sciences | ** Support | |
| California Manufacturers And Technology Association | ** Support | |
| California Pharmacists Association | ** Support | |
| California Podiatric Medical Association | ** Support | |
| California Retired Teachers Association | ** Support | |
| California Rheumatology Alliance | ** Support | |
| California State Commanders Veterans Council | ** Support | |
| Carrie’s Touch | ** Support | |
| Chronic Disease Coalition | ** Support | |
| Community Health Action Network | ** Support | |
| Crohns And Colitis Foundation | ** Support | |
| Cystic Fibrosis Research, Inc. | ** Support | |
| Depression and Bipolar Support Alliance California. | ** Support | |
| Diabetes Patient Advocacy Coalition | ** Support | |
| Epilepsy Foundation of San Diego County | ** Support | |
| Hemophilia Council Of California | ** Support | |
| Infusion Access Foundation | ** Support | |
| International Bipolar Foundation | ** Support | |
| International Foundation for Autoimmune and Inflammatory Arthritis | ** Support | |
| Keck Medicine Of University Of Southern California | ** Support | |
| Liver Coalition of San Diego | ** Support | |
| Liver Coalition of Sd | ** Support | |
| Liver Health Foundation | ** Support | |
| Looms for Lupus | ** Support | |
| Los Angeles Wellness Station | ** Support | |
| Lupus Foundation of America, Southern California Region | ** Support | |
| Lupus Foundation of Southern California | ** Support | |
| Mexican American Opportunity Foundation | ** Support | |
| Military Officers Association Of America, California Council Of Chapters | ** Support | |
| Murdoch, Walrath & Holmes | ** Support | |
| National Infusion Center Association | ** Support | |
| National Multiple Sclerosis Society, Mscan | ** Support | |
| Neighborhood Wellness Foundation | ** Support | |
| Partners in Care Foundation | ** Support | |
| Patient Pocket Protector Coalition | ** Support | |
| Pharmaceutical Care Management Association | ** Against | |
| Pharmaceutical Research And Manufacturers Of America | ** Support | |
| Several individuals | ** Support | |
| Sickle Cell Disease Foundation | ** Support | |
| Steinberg Institute | ** Support | |
| The Kennedy Forum | ** Support | |
| The Wall Las Memorias Project | ** Support | |
| Vietnam Veterans Association, California State Council | ** Support | |
| Vietnam Veterans Of America, California State Council | ** Support |
Date of Hearing: August 23, 2023
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Chris Holden, Chair
SBPCA Bill Id:SB 873
Author:(Bradford) – As Introduced Ver:February 17, 2023
Policy Committee: | Health | Vote: | 13 - 1 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health care service plan (health plan) or health insurer to calculate an enrollee’s or insured’s share of cost for a prescription drug based on a reduction equal to 90% of all rebates received, or to be received, in connection with the dispensing or administration of that drug. This bill requires the health plan or insurer to provide the dispensing pharmacy, at the point of sale, the calculated share of cost for each prescription drug for an enrollee or insured.
This bill also requires the Department of Managed Health Care (DMHC) and the Insurance Commissioner to submit an annual report on the impact of these provisions to the Legislature.
The provisions of this bill sunset on January 1, 2027.
FISCAL EFFECT:
- The California Department of Insurance (CDI) estimates costs of $269,000 in fiscal year (FY) 2023-24, $325,000 in FY 2024-25, and $12,000 per year, ongoing (Insurance Fund).
- DMHC estimates costs as follows (Managed Care Fund (MCF)):
- $5 million for 26 positions and other costs in FY 2023-24.
- $84 million and 379 positions in FY 2024-25.
- $139 million and 732 positions in FY 2025-26.
- $120 million and 733 positions (some for half of the year) in FY 2026-27.
- $52 million and 581 positions for half of the year FY 2027-28.
DMHC notes that, depending on final enrollment data, a $1 million dollar increase to the MCF could result in a 2-cent increase per enrollee on assessments to full-service health plans. To the extent this bill and others result in an additional assessment on health plans, consumers could face increased premiums.
COMMENTS:
- Purpose. According to the author:
SB 873 will ensure patients are better able to afford their medications by reforming the state’s prescription drug rebate system to ensure it benefits patients, not health care corporations. By including transparency provisions and requiring 90% of manufacturer rebates to be passed on at the pharmacy counter, patients will not only be able to better afford their medicines, they will also better adhere to their doctors’ decisions by not rationing or skipping doses due to cost. Since 2020, more than 100 similar measures have been introduced across the nation and in 2021 West Virginia passed a law (HB 2263) that requires 100% of rebates to first benefit the patient at the point-of-sale and then be used to lower premiums more broadly.
The author further contends this legislation will save the average diabetic patient $630 in out-of-pocket costs per plan year, patients with asthma will see an average decrease in out-of-pocket costs of approximately $270 annually. The author concludes the sickest patients in the healthcare system drive expenditures, so decreasing out-of-pocket costs and increasing adherence for those patients will benefit the system as a whole.
- California Health Benefit Review Program (CHBRP) Analysis. In its analysis of AB 933 (Daly), of the 2021-22 Legislative Session, which was similar to this bill, CHBRP reported:
- Utilization. 836,000 enrollees use higher cost brand-name or specialty drugs and have plan designs for which cost sharing might change if this bill were enacted. However, the actual number of impacted enrollees will be lower as not all brand-name and specialty drugs may be eligible for manufacturer rebates. Postmandate, the number of enrollees who use brand-name or specialty medications with potentially impacted cost sharing would increase to 840,000 due to a reduction in cost barriers for some enrollees.
- Expenditures. This bill would increase total net annual expenditures by $129,725,000 (0.10%) for enrollees with health insurance subject to state-level benefit mandates. This is due to a $200,558,000 increase in total health insurance premiums and a $70,833,000 decrease in enrollee share of cost for services for newly covered members.
- California Public Employees' Retirement System. CHBRP projects no measurable change to CalPERS.
- Covered California. Total premium expenditures for individually purchased coverage through Covered California would increase by $33,045,000 (0.30%).
According to CHBRP, rebates will effectively lower the price for consumers of specific drugs, which will then result in additional demand or use of those drugs. However, the spending incurred by health plans is not only focused on rebates, but the cost of all drugs that would be dispensed if the price was reduced to the patient and more utilization occurred at that lower price to consumers. The rebates would still need to be paid by someone, in this case the carrier would absorb the cost. The increase in cost to the plan can be attributed to three sources:
- A $95,880,000 increase in medical cost to the plan caused by shifting rebates from plan to patients.
- A $69,488,000 increase in medical cost to the plan caused by increase in utilization.
- A $34,632,000 increase in administrative cost to the plan caused by an increase in medical costs.
- Incentive to Use Brand-name Drugs. CHBRP reports this bill would affect enrollees who use brand-name or specialty medications, and would likely increase their number because rebates on brand-name drugs could make them less expensive to the enrollee. Additionally, a Commonwealth Fund report suggests incentives to use brand-name products may decrease the market share for generics or even discourage manufacturers from developing more of them.
- Prior Legislation.
- AB 315 (Wood), Chapter 905, Statutes of 2018, required DMHC, in collaboration with other specified entities and stakeholders, to convene a Task Force on Pharmacy Benefit Manager (PBM) Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plans or their contracted PBMs. AB 315 required the task force to consider inclusion of information including, but not limited to: wholesale acquisition cost (WAC) of pharmaceuticals; rebates; payments to network pharmacies; and, exclusivity arrangements between health plans or contracted PBMs with manufacturers.
- AB 265 (Wood), Chapter 611, Statutes of 2017, prohibited prescription drug manufacturers from offering discounts or other reductions in an individual's out of pocket expenses associated with their insurance coverage, if a lower cost therapeutically equivalent generic drug is available.
- SB 17 (Hernandez), Chapter 603, Statutes of 2017, required health plans and insurers that report rate information through the existing large and small group rate review process to also report specified information related to prescription drug pricing to DMHC and CDI. SB 17 required DMHC and CDI to compile specified information into a consumer-friendly report demonstrating the overall impact of drug costs on health care premiums, and required drug manufacturers to notify specified purchasers, at least 90 days prior to the planned effective date, if it is increasing the WAC of a prescription drug by specified amounts, among other provisions.
- AB 2942 (Daly), of the 2021-22 Legislative Session, would have required an enrollee’s or insured’s defined cost sharing for each prescription drug to be calculated at the POS based on a price that is reduced by an amount equal to 90% of all rebates received, or to be received, in connection with the dispensing or administration of the drug. The bill also would have required a health plan or health insurer to, among other things, pass through to each enrollee or insured at the POS a good faith estimate of their decrease in cost sharing. AB 2942 was not heard in Assembly Health Committee.
- SB 1361 (Kamlager), of the 2021-22 Legislative Session, would have required health plans and insurers to reduce enrollee and insured cost-sharing to reflect drug manufacturer rebates at the POS and reporting of POS rebates until 2025 and additional reporting on rebates and PBMs until 2025; terminated an existing annual report on prescription drug costs published by DMHC; established multiple definitions related to PBMs; and, required PBMs to owe a duty to enrollees, health plans, and providers. SB 1361 was held in Senate Appropriations Committee.
- AB 933 (Daly), of the 2021-22 Legislative Session, was substantially similar to this bill and was held on this committee’s suspense file.
- AB 315 (Wood), Chapter 905, Statutes of 2018, required DMHC, in collaboration with other specified entities and stakeholders, to convene a Task Force on Pharmacy Benefit Manager (PBM) Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plans or their contracted PBMs. AB 315 required the task force to consider inclusion of information including, but not limited to: wholesale acquisition cost (WAC) of pharmaceuticals; rebates; payments to network pharmacies; and, exclusivity arrangements between health plans or contracted PBMs with manufacturers.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 873 |
THIRD READING
Bill No: SB 873
Author: Bradford (D)
Introduced: 2/17/23
Vote: 21
SENATE HEALTH COMMITTEE: 8-1, 4/19/23
AYES: Eggman, Gonzalez, Limón, Menjivar, Roth, Rubio, Wahab, Wiener
NOES: Glazer
NO VOTE RECORDED: Nguyen, Dahle, Hurtado
SENATE APPROPRIATIONS COMMITTEE: 5-2, 5/18/23
AYES: Portantino, Ashby, Bradford, Wahab, Wiener
NOES: Jones, Seyarto
SUBJECT: Prescription drugs: cost sharing
SOURCE: California Access Coalition
DIGEST:
This bill requires, at the point-of-sale, the cost-sharing of an enrollee or insured of a health plan or health insurer to be reduced based on rebates received, or to be received, in connection with the dispensing or administration of the drug. This bill requires on or before March 1 each year, the Department of Managed Health Care and the Insurance Commissioner to provide a report on this bill’s impact on drug prices and health care premium rates to the appropriate policy committees of the Legislature, and makes this bill’s provisions inoperative on January 1, 2027.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers. [HSC §1340, et seq., and INS §106, et seq.]
- Requires a health plan or health insurer that reports rate information, as specified, to report information no later than October 1 of each year that demonstrates the overall impact of drug costs on health care premiums. [HSC §1356.243 and INS §10123.205]
This bill:
- Requires, no later than January 1, 2025, an enrollee’s or insured’s defined cost-sharing for each prescription drug to be calculated at the point-of-sale based on a price that is reduced by an amount equal to at least 90% of all rebates received, or to be received, in connection with the dispensing or administration of the drug.
- Requires the health plan or insurer to pass through at the point-of-sale a good faith estimate of the enrollee’s or insurer’s decrease in cost-sharing.
- Requires a health plan or insurer to provide the enrollee or insured with an end-of-calendar-year reconciliation for any cost-sharing reductions owed to the enrollee or insured that were not passed on through the estimated amount at the point-of-sale. Prohibits this from authorizing a health plan or insurer to recover from an enrollee or insured any inaccurate estimate of cost-sharing reductions.
- Requires each health plan or insurer, either directly or indirectly through its agents, to calculate the enrollee’s or insured’s defined cost-sharing and provide the dispensing pharmacy with the enrollee’s or insured’s defined cost-sharing for each prescription drug. Indicates a health plan or insurer is not prohibited from decreasing an enrollee’s or insured’s defined cost-sharing by a greater amount.
- Prohibits this bill from being interpreted or implemented in a manner inconsistent with federal law. Makes the provisions of this bill severable, so that if a provision or its application is held invalid or incapable of being enforced against a health plan or insurer due to a conflict with federal requirements, prohibits that invalidity from affecting other provisions or applications that can be given effect without the invalid provision or application.
- Requires cost-sharing, including copayments, coinsurance, deductibles, and any other form of cost-sharing to be consistent with cost-sharing copayment caps, as specified, and other provisions of the law.
- Requires, on or before March 1 of each year, DMHC and the Insurance Commissioner to provide a report on this bill’s impact on drug prices and health care premium rates to the appropriate policy committees of the Legislature.
- Requires health plans and insurers to report the following as part of an existing requirement to report on prescription drugs and their costs:
- The 25 most frequently prescribed drugs with a point-of-sale rebate; and,
- The 25 most costly drugs by total annual plan/insurer spending with a point-of-sale rebate.
- Requires for each health plan/insurer with a prescription drug benefit that the health plan/insurer to report rebate information, as specified.
- Prohibits the drug cost and rebates report compiled by DMHC or CDI from identifying a specific manufacturer, the prices charged for specific drugs, or classes of drugs, or the amount of any rebates provided for specific drugs or classes of drugs, or otherwise have the potential to compromise the financial, competitive, or proprietary nature of that information.
- Sunsets the provisions of this bill on January 1, 2027.
Comments
According to the author, this bill will ensure patients are better able to afford their medications by reforming the state’s prescription drug rebate system to ensure it benefits patients, not health care corporations. By including transparency provisions and requiring 90% of manufacturer rebates to be passed on at the pharmacy counter, patients will not only be able to better afford their medicines, they will also better adhere to their doctors’ decisions by not rationing or skipping doses due to cost. Since 2020, more than 100 similar measures have been introduced across the nation, and in 2021 West Virginia passed a law (HB 2263) that requires 100% of rebates to first benefit the patient at the point-of-sale and then be used to lower premiums more broadly.
Prescription drug costs. A February 11, 2020 white paper issued by the USC Schaeffer Center for Health Policy & Economics on “The Association between Drug Rebates and List Prices,” finds that drug rebates and list prices are positively correlated, on average, a $1 increase in rebates is associated with a $1.17 increase in list price. Single-source drugs have higher average list prices and rebates than multi-source drugs, and show a stronger relationship between changes in rebates and list prices. Rebates play a role in increasing drug prices, and reducing or eliminating rebates could result in lower list prices and reduced out-of-pocket expenditures for some patients.
California data. Health plans regulated by DMHC paid more than $10.8 billion for prescription drugs in 2021, an increase of almost $700 million or 6.6% from 2020. Total medical expenses increased by 9.2%. Enrollees spent nearly $1 billion for prescription drugs in 2021. Manufacturer drug rebates totaled approximately $1.674 billion, up from $1.437 billion in 2020 and $1.205 billion in 2019. This represents about 15.5% of the $10.8 billion spent on prescription drugs in 2021. For CDI insurers, prescription drugs accounted for 14.1% of total health care premiums in 2021 once rebates are considered, this is up from 13.4% in 2020. Prescription drugs accounted for 16.3% of all medical costs in 2021 once rebates are considered, and 16.6% for 2020. Drug costs per prescription decreased by 1.5% overall. But decreased costs per prescription were not found across all drug categories: generic drugs decreased by 3.7% in cost per prescription, while specialty drugs increased in cost per prescription by 6.1%. A portion of the increased drug costs per prescription for brand and specialty drugs was offset by the increased use of rebates in 2021.
PBMs. PBMs help health plans manage their drug benefits through negotiating or contracting with manufacturers and/or pharmacies on behalf of their contracted health plans. The DMHC PBM report required by AB 315 (Wood, Chapter 905, Statutes of 2018), indicates that PBMs receive rebates from manufactures for certain prescription drugs. The “retained rebate” is the amount of rebate the PBM receives but does not pass along to the plan. Even health plans are often unaware of the amount of the PBM’s retained rebate. Additionally, rebates may offer perverse incentives, as higher cost drugs could mean higher rebates for the PBM.
Attorney General action. In January 2023, California Attorney General Rob Bonta announced a lawsuit against the nation's largest insulin makers (Eli Lilly, Novo Nordisk, and Sanofi) and three PBMs (CVS Caremark, Express Scripts, and Optum Rx) for driving up the cost of insulin through unlawful, unfair, and deceptive business practices in violation of California's Unfair Competition Law. The lawsuit alleges these manufacturers and PBMs have leveraged their market power to overcharge patients. The complaint alleges the defendants separately conspired to artificially inflate prices while agreeing to provide secret rebates in an attempt to obtain preferred positions on drug formularies.
California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed AB 933 (Daly of 2020), which has some overlapping provisions with this bill with regard to the drug rebate provisions.
Key findings include:
Rebates. Drug rebates are used by pharmaceutical manufacturers to incentivize coverage and use for their products. Drug rebates are generally paid by a pharmaceutical manufacturer to a PBM, who then shares a portion with the health insurer. Rebates are mostly used for higher cost brand-name prescription drugs in competitive therapeutic classes where there are interchangeable products and aim to incentivize PBMs and health insurers to include the pharmaceutical manufacturer’s products on their formularies and to obtain preferred “tier” placement.
Coverage impacts and enrollees covered. Among enrollees with potentially impacted cost sharing at baseline, there are 836,000 enrollees who use brand or specialty medications. Postmandate, the number of enrollees who use brand or specialty medications with potentially impacted cost sharing would increase to 840,000. Details on manufacturer rebate programs are proprietary, such as, for instance, which drugs may have manufacturer rebates available. As such, CHBRP is unable to estimate the number of impacted individuals for which cost-sharing might change if this bill were enacted.
Individual impacts. The average retail allowed cost of brand and specialty drugs, prior to rebates, was estimated to be $992. CHBRP estimated that the net cost of brand and specialty drugs after rebates was $675 which is the average amount that would be subject to cost-sharing postmandate. However, the $318 difference between the $992 average retail allowed cost and $675 net cost of brand drugs after rebates would still be paid by insurance carriers to retail pharmacies.
Utilization. CHBRP assumed that the increase in enrollee utilization of prescription drugs due to decreased cost-sharing would be 3.5% of total prescriptions for enrollees in medium or high cost-sharing plans. CHBRP assumed that the increase in utilization is driven by a 0.5% increase in the number of enrollees utilizing brand or specialty drugs and a 3.0% increase in the utilization for enrollees utilizing brand or specialty drugs. This induced demand estimate is based upon evidence from the RAND Health Insurance Experiment, which allows for the estimation of increased use of outpatient services based on a price elasticity of −0.2.
Impact on expenditures. This bill would increase total health insurance premiums (paid by employers, employees, and individuals/families, including individuals who receive cost-sharing reductions because of this bill) by $200,558,000. For enrollees on brand name or specialty drugs with rebates, CHBRP estimates a total $70,833,000 decrease in enrollee share of cost for the brand name or specialty drug rebates passed through because of this bill. CHBRP projects total premium expenditures for individually purchased plans in Covered California to increase by $33,045,000, or 0.30%.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- Unknown ongoing costs, likely hundreds of thousands (Managed Care Fund), for DMHC to administer the provisions.
- The CDI estimates costs of $269,000 in 2023-24, $325,000 in 2024-25, and $12,000 in 2025-56 and ongoing thereafter (Insurance Fund) to administer the provisions.
SUPPORT: (Verified 5/18/23)
California Access Coalition (source)
Alliance for Patient Access
Alliance for Transparent and Affordable Prescriptions
ALS Association
American Diabetes Association
American Legion-Department of California
AMVETS-Department of California
Applied Pharmacy Solutions
Bay Area Cancer Connections
Biocom California
California Academy of Family Physicians
California Black Health Network
California Chronic Care Coalition
California Health Collaborative
California Hepatitis C Task Force
California League of United Latin American Citizens
California Life Sciences
California Manufacturers and Technology Association
California Pharmacists Association
California Podiatric Medical Association
California Retired Teachers Association
California Rheumatology Alliance
California State Commanders Veterans Council
Carrie’s Touch
Chronic Disease Coalition
Community Health Action Network
Crohn’s and Colitis Foundation
Depression and Bipolar Support Alliance California
Epilepsy Foundation of San Diego County
Hemophilia Council of California
Infusion Access Foundation
International Foundation for Autoimmune and Inflammatory Arthritis
International Bipolar Foundation
Liver Coalition of San Diego
Liver Health Foundation
Looms for Lupus
Los Angeles Wellness Station
Lupus Foundation of America, Southern California Region
Mexican American Opportunity Foundation
Military Officers Association of America-California Council of Chapters
National Infusion Center Association
National Multiple Sclerosis Society, MS-CAN
Neighborhood Wellness Foundation
Partners in Care Foundation
Pharmaceutical Research and Manufacturers of America
Sickle Cell Disease Foundation
Steinberg Institute
The Kennedy Forum
The Wall Las Memorias Project
Vietnam Veterans Association-California State Council
Several Individuals
OPPOSITION: (Verified 5/18/23)
America’s Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
Pharmaceutical Care Management Association
ARGUMENTS IN SUPPORT: The California Access Coalition writes health insurers and pharmacy middlemen, known as PBMs negotiate rebates from drug manufacturers in return for placement of the manufacturers’ medications on health plan drug formularies. These rebates average 48% of the medicine’s list price on average and create a perverse incentive for the PBMs to place the highest cost drug on the plan. In 2021, rebates totaled $1.7 billion in California alone, up from $1.4 billion in 2020 and $1.2 billion in 2019. Unfortunately, these massive payments only benefit PBMs and insurers and nothing to benefit patients. In fact, patients often end up paying nearly double for their prescriptions than the PBM and insurer pays. Due to high costs at the pharmacy counter, thousands of Californians struggle to have their prescription medications filled to treat acute or chronic conditions. Lawmakers must stand with patients and shed light on the unfair practices that leave so many struggling to afford and maintain their medications. Sharing rebates with patients at the point-of-sale will not only reduce out-of-pocket costs for patients, but it will also improve medication adherence rates – as demonstrated by UnitedHealth’s OptumRx practice of sharing rebates at the pharmacy counter, which enabled patients to save an average of $130 per eligible prescription and improved adherence rates between 4% and16%. This bill will require insurance companies pass on at least 90% of rebates to patients at the pharmacy counter, helping them afford their prescriptions in a meaningful way. The ALS Association will immediately lower out-of-pocket costs at the pharmacy counter, helping to reduce costs for families impacted by ALS. Applied Pharmacy Solutions writes that PBMs have an outsized role in the rebate system yet there are no accountability or transparency measures put in place to determine they are acting in good faith.
ARGUMENTS IN OPPOSITION: The California Chamber of Commerce writes the attention this bill directs at high drug prices is commendable, unfortunately the implementation of this bill will have weighty ramifications on employer and employee health care costs. This bill could increase employer health care premiums by nearly $109 million. Employee premiums could also increase over $41 million. Thus, the benefits of this bill would likely be concentrated among patients who use highly rebated drugs while this global cost increase would impact all insured and plan members in California. When looking at health care cost increases in isolation they seem tolerable, however, this bill must be considered in context. Premiums for employers and enrollees consistently increase year after year due to a number of issues including benefit mandates. The California Association of Health Plans (CAHP), the Association of California Life and Health Insurance Companies (ACLHIC), and America’s Health Insurance Plans (AHIP) write point of service rebates won’t help the majority of patients who take generic drugs, which account for more than 90% of the market. This bill will also not help patients who take brand name drugs that do not have competition in their therapeutic class, since rebates are generally not offered for those drugs. Furthermore, this bill does nothing to help uninsured patients afford the drugs that they need. CAHP, ACLHIC and AHIP indicate that when the Trump administration adopted a similar mandate in the Medicare Part D program, federal actuaries estimated that it would increase premiums by 25%, costs taxpayers between $200 and $400 billion, and lead to a $137 billion windfall for pharmaceutical manufacturers.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
5/20/23 13:09:53
**** END ****
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
SB 873 (Bradford) - Prescription drugs: cost sharing
Version: February 17, 2023 | Policy Vote: HEALTH 8 - 1 |
Urgency: No | Mandate: Yes |
Hearing Date: May 1, 2023 | Consultant: Agnes Lee |
Bill Summary:
SB 873 would require, at the point-of-sale, the cost-sharing of an enrollee or insured of a health plan or health insurer for prescription drugs to be reduced based on rebates received, or to be received, in connection with the dispensing or administration of the drug. The bill would require the Department of Managed Health Care and the Insurance Commissioner to provide a report on the impact of the bill’s provisions on drug prices and health care premium rates to the appropriate policy committees of the Legislature.
Fiscal Impact:
- Unknown ongoing costs, likely hundreds of thousands (Managed Care Fund), for the Department of Managed Health Care to administer the provisions.
- The Department of Insurance estimates costs of $269,000 in 2023-24, $325,000 in 2024-25, and $12,000 in 2025-56 and ongoing thereafter (Insurance Fund) to administer the provisions.
Background:
The Department of Managed Health Care (DMHC) regulates health plans under the Knox-Keene Act and the California Department of Insurance (CDI) regulates health insurance. Current law requires a health plan or health insurer that reports rate information, as specified, to report information no later than October 1 of each year that demonstrates the overall impact of drug costs on health care premiums.
Current law defines a Pharmacy Benefit Manager (PBM) as a person, business, or other entity that, pursuant to a contract with a health plan, manages the prescription drug coverage provided by the health plan, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs.
PBMs help health plans manage their drug benefits through negotiating or contracting with manufacturers and/or pharmacies on behalf of their contracted health plans. A DMHC report indicates that PBMs receive rebates from manufactures for certain prescription drugs. The “retained rebate” is the amount of rebate the PBM receives but does not pass along to the plan. Even health plans are often unaware of the amount of the PBM’s retained rebate. Additionally, rebates may offer perverse incentives, as higher cost drugs could mean higher rebates for the PBM. PBMs pay pharmacies on behalf of health plans. “Spread pricing” is the difference between the payment the PBM negotiates with the health plan and the amount the PBM pays the pharmacy. When a PBM pays the pharmacy less than the health plan pays the PBM, the PBM makes money on the difference (the “spread”). As with retained rebate amounts, the “spread” is often known only to the PBM. PBMs receive negotiated payments (or fees) from manufacturers to reimburse pharmacies and cover the PBM’s administrative expenses. The amount of these fees is unknown. PBMs may also receive per member per month payments from the health plans with which they contract.
Proposed Law:
Specific provisions of the bill would:
- Require an enrollee’s or insured’s defined cost sharing for each prescription drug to be calculated at the point of sale based on a price that is reduced by an amount equal to at least 90 percent of all rebates received, or to be received, in connection with the dispensing or administration of the drug.
- Require a health care service plan or health insurer to, among other things, pass through to each enrollee or insured at the point of sale a good faith estimate of the enrollee’s or insured’s decrease in cost sharing.
- Require a health care service plan or health insurer to calculate an enrollee’s or insured’s defined cost sharing and provide that information to the dispensing pharmacy, as specified.
- Require the DMHC and the Insurance Commissioner to submit an annual report on the impact of the above provisions on drug prices and health care premium rates to the appropriate policy committees of the Legislature, as specified.
- Require a health care service plan or health insurer that files certain rate information to report to the appropriate department additional specified cost information regarding covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs, as provided.
- Sunset the provisions of this bill on January 1, 2027.
Related Legislation:
SB 1361 (Kamlager, 2022) was similar to this bill. The bill was held on the suspense file in this committee. AB 2942 (Daly, 2022) and AB 933 (Daly, 2021) were similar to this bill. AB 2942 was never heard in the Assembly Health Committee and AB 933 was held in the Assembly Appropriations Committee.
Staff Comments:
According to the California Health Benefits Review Program (CHBRP) analysis of AB 933 (Daly, 2021), AB 933 would have increased total net annual expenditures by $129,725,000 for enrollees with health insurance subject to state-level benefit mandates. This assumed a $200,588,000 increase in total health insurance premiums and a $70,833,000 decrease in enrollee share of cost for services. The analysis estimated no changes to CalPERS health plan expenditures.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Susan Talamantes Eggman, Chair
BILL NO: SB 873
AUTHOR: | Bradford | ||
VERSION: | February 17, 2023 | ||
HEARING DATE: | April 19, 2023 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Prescription drugs: cost-sharing
SUMMARY:
Requires, at the point-of-sale, the cost-sharing of an enrollee or insured of a health plan or health insurer to be reduced based on rebates received, or to be received, in connection with the dispensing or administration of the drug. Requires on or before March 1 each year, the Department of Managed Health Care and the Insurance Commissioner to provide a report on this bill’s impact on drug prices and health care premium rates to the appropriate policy committees of the Legislature. Makes this bill’s provisions inoperative on January 1, 2027.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers. [HSC §1340, et seq., and INS §106, et seq.]
- Requires a health plan or health insurer that reports rate information, as specified, to report information no later than October 1 of each year that demonstrates the overall impact of drug costs on health care premiums. [HSC §1356.243 and INS §10123.205]
- Requires health plans and insurers, for all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, to report:
- The 25 most frequently prescribed drugs;
- The 25 most costly drugs by total annual plan spending; and,
- The 25 drugs with the highest year-over-year increase in total annual plan spending. [HSC §1356.243 and INS §10123.205]
- Requires DMHC and CDI to compile the information from 3) above into a report for the public and Legislators where the data is aggregated and does not reveal information specific to individual plans. Requires the report to be published on DMHC’s and CDI’s websites. [HSC §1356.243 and INS §10123.205]
- Defines a “Pharmacy Benefit Manager or PBM” as a person, business, or other entity that, pursuant to a contract with a health plan, manages the prescription drug coverage provided by the health plan, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs. Specifies that a licensed health plan or any individual employee of a health plan or its contracted provider is not a PBM. [HSC §1385.001]
- Requires a health plan that contracts with a PBM to require the PBM to comply with specified requirements including register with DMHC and exercise good faith and fair dealing in the performance of its duties, and comply with existing law that prohibits a contract from barring a pharmacy provider from informing a patient of a less costly alternative to a prescribed medication. [HSC §1385.004 and §1385.005]
- Requires the failure by a health plan to comply with specified contractual requirements to constitute grounds for disciplinary action. Requires the DMHC director, as appropriate, to investigate and take enforcement action against a health plan that fails to comply with these requirements and to periodically evaluate contracts between health plans and PBMs to determine if any audit, evaluation, or enforcement actions should be undertaken by DMHC. [HSC §1385.006]
- Establishes, as California's essential health benefits (EHBs) benchmark, the Kaiser Small Group Health Maintenance Organization, existing California mandates, and ten Affordable Care Act (ACA) mandated benefits, including prescription drugs. [HSC §1367.005 and INS §10112.27]
- Prohibits, with respect to an individual or group health plan contract or health insurance policy that covers EHBs, the copayment, coinsurance, or any other form of cost-sharing for a covered outpatient prescription drug for an individual prescription for a supply of up to 30 days from exceeding $250; for a product with an actuarial value at or equivalent to a Bronze level, limits cost-sharing to not more than $500 for a supply of up to 30 days; and for a high deductible health plan the $250 or $500 limits apply only after an enrollee’s deductible is met. [HSC §1342.73 and INS §10123.1932]
- Prohibits a non-grandfathered individual or small group health plan contract or insurance policy from having an annual deductible for outpatient drugs, if any, from exceeding twice the amount specified in 9) above. [HSC §1342.73 and INS §10123.1932]
This bill:
- Requires, no later than January 1, 2025, an enrollee’s or insured’s defined cost-sharing for each prescription drug to be calculated at the point-of-sale based on a price that is reduced by an amount equal to at least 90% of all rebates received, or to be received, in connection with the dispensing or administration of the drug.
- Requires the health plan or insurer to pass through at the point-of-sale a good faith estimate of the enrollee’s or insurer’s decrease in cost-sharing.
- Requires a health plan or insurer to provide the enrollee or insured with an end-of-calendar-year reconciliation for any cost-sharing reductions owed to the enrollee or insured that were not passed on through the estimated amount at the point-of-sale. Prohibits this from authorizing a health plan or insurer to recover from an enrollee or insured any inaccurate estimate of cost-sharing reductions.
- Requires each health plan or insurer, either directly or indirectly through its agents, to calculate the enrollee’s or insured’s defined cost-sharing and provide the dispensing pharmacy with the enrollee’s or insured’s defined cost-sharing for each prescription drug. Indicates a health plan or insurer is not prohibited from decreasing an enrollee’s or insured’s defined cost-sharing by a greater amount.
- Prohibits this bill from being interpreted or implemented in a manner inconsistent with federal law. Makes the provisions of this bill severable, so that if a provision or its application is held invalid or incapable of being enforced against a health plan or insurer due to a conflict with federal requirements, prohibits that invalidity from affecting other provisions or applications that can be given effect without the invalid provision or application.
- Requires cost-sharing, including copayments, coinsurance, deductibles, and any other form of cost-sharing to be consistent with cost-sharing copayment caps, as specified, and other provisions of the law.
- Establishes the following definitions:
- “Defined cost-sharing” means a deductible payment or coinsurance amount imposed for a covered prescription drug under the health plan contract or health insurance policy.
- “Price protection rebate” means a negotiated price concession that accrues directly or indirectly to a health plan, health insurer or other party on behalf of the health plan or insurer, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.
- “Rebate” means both of the following:
- Negotiated price concessions, including base price concessions, whether or not described as a “rebate,” and reasonable, good faith estimates of price protection rebates and performance-based price concessions from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug that may accrue directly or indirectly to the health plan, health insurer or other party on behalf of the health plan or insurer, including, but not limited to, health plan or insurer-owned PBMs, during a calendar year; and,
- Reasonable, good faith estimates of negotiated price concessions, fees, and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the health plan or insurer and serve to reduce the health plan’s or insurer’s liabilities for a prescription drug.
- Requires, on or before March 1 of each year, DMHC and the Insurance Commissioner to provide a report on this bill’s impact on drug prices and health care premium rates to the appropriate policy committees of the Legislature.
- Requires health plans and insurers to report the following as part of an existing requirement to report on prescription drugs and their costs:
- The 25 most frequently prescribed drugs with a point-of-sale rebate; and,
- The 25 most costly drugs by total annual plan/insurer spending with a point-of-sale rebate.
- Requires for each health plan/insurer with a prescription drug benefit that the health plan/insurer issued for delivery, renewed, amended, or continued during the immediately preceding calendar year, all of the following:
- The aggregate dollar amount of all rebates that the plan/insurer or a designee collected directly or indirectly from all pharmaceutical manufacturers in connection with the design and administration of the plan/insurer, which are attributable to enrollee or insured drug utilization during that calendar year;
- The percentage of those rebates made available to enrollees/insureds to reduce cost-sharing for prescription drugs at the point-of-sale;
- The percentage of those rebates that the health plan/insurer utilized to reduce the portion of premiums allocated to each of prescription drug expenditures, hospital expenditures, medical expenditures, administrative costs, and other expenditures; and,
- The aggregate dollar amount of all administrative service fees that the plan/insurer or a designee paid to a PBM or its designee in connection with the PBM’s managing or administering the pharmacy benefit and administering, invoicing, allocating, and collecting rebates.
- Prohibits the drug cost and rebates report compiled by DMHC or CDI from identifying a specific manufacturer, the prices charged for specific drugs, or classes of drugs, or the amount of any rebates provided for specific drugs or classes of drugs, or otherwise have the potential to compromise the financial, competitive, or proprietary nature of that information.
- Defines “health plan/insurer administrative service fees” as fees or payments from a health plan/insurer to, or otherwise retained by, a PBM or its designee pursuant to a contract between a PBM or affiliate and the health plan/insurer in connection with the PBM’s managing or administering the pharmacy benefit and administering, invoicing, allocating and collecting rebates.
- Sunsets the provisions of this bill on January 1, 2027.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, this bill will ensure patients are better able to afford their medications by reforming the state’s prescription drug rebate system to ensure it benefits patients, not health care corporations. By including transparency provisions and requiring 90% of manufacturer rebates to be passed on at the pharmacy counter, patients will not only be able to better afford their medicines, they will also better adhere to their doctors’ decisions by not rationing or skipping doses due to cost. Since 2020, more than 100 similar measures have been introduced across the nation, and in 2021 West Virginia passed a law (HB 2263) that requires 100% of rebates to first benefit the patient at the point-of-sale and then be used to lower premiums more broadly.
- Kaiser Family Foundation Survey, 2021. From an individual perspective, prescription drug affordability is a bigger issue for those who are currently taking four or more prescription medicines. Three in ten of those taking four or more prescription drugs say they have difficulty affording their prescriptions, compared to one in five adults who currently take three or fewer prescription medications. Those who take four or more prescription drugs, those with chronic conditions in their households, and those with an annual household income of less than $40,000 report having much more difficulty affording prescriptions.
- Prescription drug costs. According to the 2021 U.S. National Health Expenditures (NHE) report, NHE grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP). Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE. Out-of-pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE. Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020. Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020. Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020. The largest shares of total health spending were sponsored by the federal government (34%) and households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%.
A February 11, 2020 white paper issued by the USC Schaeffer Center for Health Policy & Economics on “The Association between Drug Rebates and List Prices,” finds that drug rebates and list prices are positively correlated, on average, a $1 increase in rebates is associated with a $1.17 increase in list price. Single-source drugs have higher average list prices and rebates than multi-source drugs, and show a stronger relationship between changes in rebates and list prices. Rebates play a role in increasing drug prices, and reducing or eliminating rebates could result in lower list prices and reduced out-of-pocket expenditures for some patients. - California data. Health plans regulated by DMHC paid more than $10.8 billion for prescription drugs in 2021, an increase of almost $700 million or 6.6% from 2020. Total medical expenses increased by 9.2%. Enrollees spent nearly $1 billion for prescription drugs in 2021. Manufacturer drug rebates totaled approximately $1.674 billion, up from $1.437 billion in 2020 and $1.205 billion in 2019. This represents about 15.5% of the $10.8 billion spent on prescription drugs in 2021. While specialty drugs accounted for only 1.6% of all prescription drugs dispensed, they accounted for 62.9% of total annual spending on prescription drugs. Generic drugs accounted for 88.2% of all prescribed drugs but only 16.3% of the total annual spending on prescription drugs. Brand name drugs accounted for 10.2% of prescriptions and constituted 20.8% of the total annual spending on prescription drugs. According to a March 16, 2022, DMHC public meeting on rates and drug costs, for 2021, average health plan premium rate increases in the large group market were just over 4% (4.1-4.2%). Average health plan rate increases in the small group market ranged from 1.7% to 3.7% with total weighted average of 1.8%, and in the individual market health plan total weighted average premium rate decreased 4%.
For CDI insurers, prescription drugs accounted for 14.1% of total health care premiums in 2021 once rebates are considered, this is up from 13.4% in 2020. Prescription drugs accounted for 16.3% of all medical costs in 2021 once rebates are considered, and 16.6% for 2020. Drug costs per prescription decreased by 1.5% overall. But decreased costs per prescription were not found across all drug categories: generic drugs decreased by 3.7% in cost per prescription, while specialty drugs increased in cost per prescription by 6.1%. A portion of the increased drug costs per prescription for brand and specialty drugs was offset by the increased use of rebates in 2021. - PBMs. PBMs help health plans manage their drug benefits through negotiating or contracting with manufacturers and/or pharmacies on behalf of their contracted health plans. The DMHC PBM report required by AB 315 (Wood, Chapter 905, Statutes of 2018), indicates that PBMs receive rebates from manufactures for certain prescription drugs. The “retained rebate” is the amount of rebate the PBM receives but does not pass along to the plan. Even health plans are often unaware of the amount of the PBM’s retained rebate. Additionally, rebates may offer perverse incentives, as higher cost drugs could mean higher rebates for the PBM. PBMs pay pharmacies on behalf of health plans. “Spread pricing” is the difference between the payment the PBM negotiates with the health plan and the amount the PBM pays the pharmacy. When a PBM pays the pharmacy less than the health plan pays the PBM, the PBM makes money on the difference (the “spread”). As with retained rebate amounts, the “spread” is often known only to the PBM and may contribute to rising prescription drug costs. PBMs receive negotiated payments (or fees) from manufacturers to reimburse pharmacies and cover the PBM’s administrative expenses. The amount of these fees is unknown. PBMs may also receive per member per month payments from the health plans with which they contract.
- DMHC PBM Task Force recommendations. AB 315, among other provisions, requires DMHC to convene a Task Force on PBM Reporting to determine what information related to pharmaceutical costs, if any, DMHC should require to be reported by health plans or their contracted PBMs. The Legislature recognized that any recommendation would be in addition to information already reported pursuant to SB 17 (Hernandez, Chapter 603, Statutes of 2017) reporting requirements. The Task Force met from July 2019 to December 2019 and developed a recommendation requiring PBMs to report data related to the services PBMs provide for commercial health plans directly to the DMHC. PBMs would be required to report drug-specific data as well as aggregated information on PBMs, including revenue and expense information. At the drug level, the Task Force recommends requiring PBMs to report the following:
- A list of the 100 most costly drugs, the 100 most frequently prescribed drugs, and the 100 highest revenue-producing drugs, grouped by generic, brand, specialty, and other; and,
- For each drug that falls into the above categories:
- The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies; and,
- Pricing and rebate information, including the amount of rebate the PBM receives from the manufacturer, the amount of rebate the PBM passes to the health plan, the amount the health plan pays the PBM, and the amount the PBM pays the pharmacy.
At an aggregated level, the Task Force recommends gathering information on PBMs, including revenue and expense information, to determine PBM market impact and the value PBMs provide to consumers. This information would include reporting on the following:
- The health plans with which the PBM contracts, the scope of services provided to the health plan, and the number of enrollees served by the PBM;
- PBM revenue, including revenue from manufacturers, health plans, pharmacies, and other revenue; and,
- PBM expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
- Attorney General action. In January 2023, California Attorney General Rob Bonta announced a lawsuit against the nation's largest insulin makers (Eli Lilly, Novo Nordisk, and Sanofi) and three PBMs (CVS Caremark, Express Scripts, and Optum Rx) for driving up the cost of insulin through unlawful, unfair, and deceptive business practices in violation of California's Unfair Competition Law. The lawsuit alleges these manufacturers and PBMs have leveraged their market power to overcharge patients. The complaint alleges the defendants separately conspired to artificially inflate prices while agreeing to provide secret rebates in an attempt to obtain preferred positions on drug formularies.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed AB 933 (Daly of 2020), which has some overlapping provisions with this bill with regard to the drug rebate provisions. Key findings include:
- Rebates. Drug rebates are used by pharmaceutical manufacturers to incentivize coverage and use for their products. Drug rebates are generally paid by a pharmaceutical manufacturer to a PBM, who then shares a portion with the health insurer. Rebates are mostly used for higher cost brand-name prescription drugs in competitive therapeutic classes where there are interchangeable products and aim to incentivize PBMs and health insurers to include the pharmaceutical manufacturer’s products on their formularies and to obtain preferred “tier” placement.
- Coverage impacts and enrollees covered. Among enrollees with potentially impacted cost sharing at baseline, there are 836,000 enrollees who use brand or specialty medications. Postmandate, the number of enrollees who use brand or specialty medications with potentially impacted cost sharing would increase to 840,000. Details on manufacturer rebate programs are proprietary, such as, for instance, which drugs may have manufacturer rebates available. As such, CHBRP is unable to estimate the number of impacted individuals for which cost-sharing might change if this bill were enacted.
- Individual impacts. The average retail allowed cost of brand and specialty drugs, prior to rebates, was estimated to be $992. CHBRP estimated that the net cost of brand and specialty drugs after rebates was $675 which is the average amount that would be subject to cost-sharing postmandate. However, the $318 difference between the $992 average retail allowed cost and $675 net cost of brand drugs after rebates would still be paid by insurance carriers to retail pharmacies:
- For example, consider an enrollee with a $1,400 overall (medical and pharmacy) deductible filling a one-time medication with a $1,000 retail allowed cost with 50% rebates at baseline. If this enrollee fills the medication prior to any other health care expenditure, at baseline, their cost-sharing would be $1,000. As total manufacturer rebates are $500, and 90% of this value is passed through to the enrollee, then the enrollee would see a reduction in the allowable retail cost subject to cost-sharing of $450 (90% of $500). Postmandate, the cost-sharing would drop by 45% to $550, the new retail allowed cost after rebates, which would be used to calculate cost-sharing.
- As another example, consider an enrollee with a $5,000 maximum out-of-pocket who has met this amount for the year. This enrollee would have no cost-sharing at baseline. Similarly, regardless of the rebates available, the enrollee would have no cost-sharing postmandate. For any enrollee who meets their maximum out-of-pocket amount both at baseline and postmandate, the bill has no impact on out-of-pocket expenditure.
- Utilization. CHBRP assumed that the increase in enrollee utilization of prescription drugs due to decreased cost-sharing would be 3.5% of total prescriptions for enrollees in medium or high cost-sharing plans. CHBRP assumed that the increase in utilization is driven by a 0.5% increase in the number of enrollees utilizing brand or specialty drugs and a 3.0% increase in the utilization for enrollees utilizing brand or specialty drugs. This induced demand estimate is based upon evidence from the RAND Health Insurance Experiment, which allows for the estimation of increased use of outpatient services based on a price elasticity of −0.2.
- Impact on expenditures. This bill would increase total health insurance premiums (paid by employers, employees, and individuals/families, including individuals who receive cost-sharing reductions because of this bill) by $200,558,000. For enrollees on brand name or specialty drugs with rebates, CHBRP estimates a total $70,833,000 decrease in enrollee share of cost for the brand name or specialty drug rebates passed through because of this bill. CHBRP projects total premium expenditures for individually purchased plans in Covered California to increase by $33,045,000, or 0.30%.
- Long-term impacts. The enrollees most likely to benefit from this bill in the long-term are those with conditions that require treatment with higher cost brand-name or specialty drugs, which are typically more expensive out-of-pocket. In the long-term, this bill would reduce out-of-pocket spending on those drugs subject to rebates for those enrollees. As brand-name drugs lose their patent protection or face more competition, the relative value of certain existing rebates will decrease while new drugs with rebates will enter the market. The net allowed retail cost used to calculate cost-sharing will shift as the use of rebates shift, such that consumers may also experience shifts in the out-of-pocket cost-sharing they pay for prescription drugs. It is unclear how manufacturers, insurance companies, and PBMs may respond to this bill in the long-term. Because this bill would only change the law in California and impacts less than 10% of the enrollees in the DMHC- and CDI-regulated insurance market, it is unlikely to impact the use of rebates by manufacturers in the long-term. However, insurers that do a substantial amount of business in California might be incentivized by this bill to renegotiate how rebates are passed through or used to compensate PBMs in future contracts.
- Rebates. Drug rebates are used by pharmaceutical manufacturers to incentivize coverage and use for their products. Drug rebates are generally paid by a pharmaceutical manufacturer to a PBM, who then shares a portion with the health insurer. Rebates are mostly used for higher cost brand-name prescription drugs in competitive therapeutic classes where there are interchangeable products and aim to incentivize PBMs and health insurers to include the pharmaceutical manufacturer’s products on their formularies and to obtain preferred “tier” placement.
- Medicare Part D. According to a 2022 federal Office of Inspector General (OIG) report, following the introduction of authorized generic versions of two brand-name hepatitis C drugs-Epclusa and Harvoni-in 2019, use of the authorized generic versions increased in Medicaid at greater rates than in Medicare Part D. In 2020, some Part D plans did not cover the authorized generics, limiting beneficiary access to less costly options. Medicare beneficiaries also were less likely to use other lower-cost brand-name options in 2020 compared to Medicaid beneficiaries. Although rebates from manufacturers reduced overall Part D spending for higher-cost hepatitis C drugs (like Epclusa and Harvoni), they provided little relief to beneficiaries or the Medicare program. Part D beneficiaries without financial assistance paid, on average, $2,200 more out of pocket for higher-cost hepatitis C drugs in 2020. Further, Medicare's average catastrophic coverage payment for a beneficiary prescribed a higher-cost drug was over $8,000 more compared to a beneficiary prescribed a lower-cost drug. As a result, Medicare spent $155 million more in catastrophic coverage payments for higher-cost hepatitis C drugs, despite a similar number of beneficiaries in each cost group reaching catastrophic coverage. OIG's findings about utilization trends for higher-cost hepatitis C drugs in Medicare align with experts' suggestions that certain programmatic factors, such as manufacturer rebates, may be providing incentives for Part D plan sponsors to prefer their enrollees use higher-cost drugs. Federal rules have been issued to require PBM and Medicare Part D plans to abandon the use of rebates unless they are passed on to the
consumer at the point of sale. The rule is effective January 1, 2024. - Prior legislation. SB 1361 (Kamlager of 2022) would have required health plans and insurers to reduce enrollee and insured cost-sharing to reflect drug manufacturer rebates at the point-of-sale and reporting of point-of-sale rebates until 2025 and additional reporting on rebates and PBMs until 2025; terminated an existing annual report on prescription drug costs published by DMHC; established multiple definitions related to PBMs; and, required PBMs to owe a duty to enrollees, health plans, and providers. SB 1361 was held in the Senate Appropriations Committee.
AB 2942 (Daly of 2022) would have required a health plan or insurer to define cost-sharing for a prescription drug to be calculated at the point-of-sale based on a price that is reduced by an amount equal to 90% of all rebates received, or expected to be received, in connection with the dispensing or administration of the drug; and, to provide an enrollee or insured with an end-of-calendar-year reconciliation for any cost-sharing reductions owed to the enrollee or insured that were not passed on to the enrollee or insured at the point-of-sale. AB 2942 would have required DMHC and the Insurance Commissioner to annually report on the impact of those provisions on drug prices and health care premium rates, as specified. AB 2942 was never scheduled for a hearing in the Assembly Health Committee.
AB 933 (Daly of 2020) was substantially similar to AB 2942. AB 933 was held in the Assembly Appropriations Committee.
SB 17 (Hernandez, Chapter 603, Statutes of 2017) requires health plans and insurers that report rate information through the existing large and small group rate review process to also report specified information related to prescription drug pricing to DMHC and CDI. SB 17 requires DMHC and CDI to compile specified information into a consumer-friendly report that demonstrates the overall impact of drug costs on health care premiums. SB 17 requires drug manufacturers to notify specified purchasers, in writing at least 90 days prior to the planned effective date, if it is increasing the WAC of a prescription drug by specified amounts. SB 17 requires drug manufacturers to notify the Department of Health Care Access and Information (HCAI) when introducing a new drug to market at a WAC that exceeds the Medicare Part D specialty drug threshold, and to provide specified information to HCAI related to the drug’s price.
AB 315 (Wood, Chapter 905, Statutes of 2018) requires PBMs to register with DMHC, to exercise good faith and fair dealing, and to disclose, upon a purchaser's request, information with respect to prescription product benefits, as specified. AB 315 requires DMHC to convene a Task Force on PBM Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plan or their contracted PBMs. AB 315 establishes a pilot project in Riverside and Sonoma Counties to assess the impact of health plan and PBM prohibitions that prohibit the dispensing of certain amounts of prescription drugs by network retail pharmacies.
- Support. The California Access Coalition writes health insurers and pharmacy middlemen, known as PBMs negotiate rebates from drug manufacturers in return for placement of the manufacturers’ medications on health plan drug formularies. These rebates average 48% of the medicine’s list price on average and create a perverse incentive for the PBMs to place the highest cost drug on the plan. In 2021, rebates totaled $1.7 billion in California alone, up from $1.4 billion in 2020 and $1.2 billion in 2019. Unfortunately, these massive payments only benefit PBMs and insurers and nothing to benefit patients. In fact, patients often end up paying nearly double for their prescriptions than the PBM and insurer pays. Due to high costs at the pharmacy counter, thousands of Californians struggle to have their prescription medications filled to treat acute or chronic conditions. Lawmakers must stand with patients and shed light on the unfair practices that leave so many struggling to afford and maintain their medications. Sharing rebates with patients at the point-of-sale will not only reduce out-of-pocket costs for patients, but it will also improve medication adherence rates – as demonstrated by UnitedHealth’s OptumRx practice of sharing rebates at the pharmacy counter, which enabled patients to save an average of $130 per eligible prescription and improved adherence rates between 4% and16%. This bill will require insurance companies pass on at least 90% of rebates to patients at the pharmacy counter, helping them afford their prescriptions in a meaningful way. The ALS Association will immediately lower out-of-pocket costs at the pharmacy counter, helping to reduce costs for families impacted by ALS. Applied Pharmacy Solutions writes that PBMs have an outsized role in the rebate system yet there are no accountability or transparency measures put in place to determine they are acting in good faith.
- Opposition. The California Chamber of Commerce writes the attention this bill directs at high drug prices is commendable, unfortunately the implementation of this bill will have weighty ramifications on employer and employee health care costs. CHBRP did not have an opportunity to review this bill but it is nearly identical to AB 933 which was analyzed by CHBRP. It was determined that if AB 933 went into effect, it would increase employer health care premiums by nearly $109 million. Employee premiums would also increase over $41 million. Thus, the benefits of this bill would likely be concentrated among patients who use highly rebated drugs while this global cost increase would impact all insured and plan members in California. Specifically, patients who are prescribed lower cost or generic brand drugs will pay higher premiums but not reap point of service savings as the bill intends. When looking at health care cost increases in isolation they seem tolerable, however, this bill must be considered in context. Premiums for employers and enrollees consistently increase year after year due to a number of issues including benefit mandates. The 2022 Kaiser Family Foundation Employer Health Benefits Survey indicated that the average premium for family coverage has increased 20% over the last five years and 43% over the last 10 years. Additionally, annual premiums for employer-sponsored family health coverage reached $22,463 in 2022, with workers on average paying $6,106 toward the cost of their coverage. California must remain mindful when increasing the cost of health care coverage costs through legislation. The California Association of Health Plans (CAHP), the Association of California Life and Health Insurance Companies (ACLHIC), and America’s Health Insurance Plans (AHIP) write point of service rebates won’t help the majority of patients who take generic drugs, which account for more than 90% of the market. This bill will also not help patients who take brand name drugs that do not have competition in their therapeutic class, since rebates are generally not offered for those drugs. In fact, CHBRP estimated that a similar bill (AB 933, Daly of 2022) would only impact 3.48% of all prescriptions but it increases health insurance premiums by $200 million annually. Furthermore, this bill does nothing to help uninsured patients afford the drugs that they need. CAHP, ACLHIC and AHIP indicate that when the Trump administration adopted a similar mandate in the Medicare Part D program, federal actuaries estimated that it would increase premiums by 25%, costs taxpayers between $200 and $400 billion, and lead to a $137 billion windfall for pharmaceutical manufacturers. The Senate Appropriations Committee refused to advance that bill due to the increased premium cost; Congress has continually disallowed the federal “rebate rule” to take effect. Furthermore, nothing in this bill addresses the root cause of high drug cost for consumers, which is high list prices set by manufacturers. This legislation would allow pharmaceutical manufacturers to continue to raise their prices year after year, which will increase the cost of this mandate even further.
SUPPORT AND OPPOSITION:
Support: California Access Coalition (sponsor)
Alliance for Patient Access
ALS Association
American Diabetes Association
American Legion-Department of California
AMVETS-Department of California
Applied Pharmacy Solutions
Bay Area Cancer Connections
Biocom California
California Academy of Family Physicians
California Black Health Network
California Chronic Care Coalition
California Health Collaborative
California Hepatitis C Task Force
California League of United Latin American Citizens
California Life Sciences
California Manufacturers and Technology Association
California Podiatric Medical Association
California Retired Teachers Association
California Rheumatology Alliance
California State Commanders Veterans Council
Community Health Action Network
Crohn’s and Colitis Foundation
Depression and Bipolar Support Alliance California
Hemophilia Council of California
International Foundation for Autoimmune and Inflammatory Arthritis
International Bipolar Foundation
Liver Coalition of San Diego
Liver Health Foundation
Looms for Lupus
Los Angeles Wellness Station
Lupus Foundation of America, Southern California Region
Mexican American Opportunity Foundation
Military Officers Association of America-California Council of Chapters
National Multiple Sclerosis Society, MS-CAN
Neighborhood Wellness Foundation
Partners in Care Foundation
Pharmaceutical Research and Manufacturers of America
Sickle Cell Disease Foundation
Steinberg Institute
The Kennedy Forum
The Wall Las Memorias Project
Vietnam Veterans Association-California State Council
Several Individuals
Oppose: America’s Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
Pharmaceutical Care Management Association
-- END --
Discussed in Hearing
Assembly Standing Committee on Health
Senate Floor
Senate Standing Committee on Appropriations
Senate Standing Committee on Health
Bill Author
Bill Co-Author(s):